Show simple item record

dc.contributor.authorPapathanou, Maria
dc.contributor.authorJenner, Peter
dc.contributor.authorIravani, Mahmoud M.
dc.contributor.authorJackson, Michael
dc.contributor.authorStockwell, Kim
dc.contributor.authorStrang, Isobel
dc.contributor.authorZeng, Bai-Yun
dc.contributor.authorMcCreary, Andrew
dc.contributor.authorRose, Sarah
dc.date.accessioned2014-09-23T14:30:54Z
dc.date.available2014-09-23T14:30:54Z
dc.date.issued2014-10-15
dc.identifier.citationPapathanou , M , Jenner , P , Iravani , M M , Jackson , M , Stockwell , K , Strang , I , Zeng , B-Y , McCreary , A & Rose , S 2014 , ' The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats ' , European Journal of Pharmacology , vol. 741 , pp. 304-310 . https://doi.org/10.1016/j.ejphar.2014.08.004
dc.identifier.issn0014-2999
dc.identifier.otherPURE: 7414064
dc.identifier.otherPURE UUID: ee2e49f9-4e3c-44ea-8d86-b8d3d5b71a98
dc.identifier.otherScopus: 84907079315
dc.identifier.otherORCID: /0000-0002-4905-9682/work/32997567
dc.identifier.urihttp://hdl.handle.net/2299/14457
dc.description.abstractThe treatment of dyskinesia in Parkinson׳s disease remains poor but H3 receptor agonists have been suggested as a novel pharmacological approach. We examined the effects of the H3 agonist, immepip, in 6-OHDA-lesioned rats exhibiting AIMs (abnormal involuntary movements), a rat analogue of dyskinesia, in response to l-dopa compared to the known anti-dyskinetic agents amantadine, MK-801 and 8-OHDPAT. We then attempted to extend these studies in to dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated common marmosets. Amantadine, MK-801 and 8-OHDPAT all dose-dependently reduced l-dopa-induced axial, lingual and oral (ALO) AIMs in 6-OHDA-lesioned animals accompanied by a reduction in contralateral rotation with higher doses of amantadine and MK-801. By contrast, immepip had no effect on AIMs expression or contralateral rotation. In the MPTP-treated common marmoset exhibiting dyskinesia to l-dopa, immepip alone induced retching and in combination with l-dopa administered subcutaneously or orally induced the rapid onset of retching and vomiting which was not controlled by pretreatment with domperidone. Administration of the unrelated H3 agonist, imetit had the same effect. Despite causing negative side-effects, it appears that both agonists reduced the antiparkinsonian response to l-dopa resulting in reduced dyskinesia. H3 agonists appear unlikely candidates for the treatment of dyskinesia in PD based on lack of evidence of efficacy and potential adverse effects.en
dc.language.isoeng
dc.relation.ispartofEuropean Journal of Pharmacology
dc.titleThe H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned ratsen
dc.contributor.institutionNeurodegenerative Diseases
dc.contributor.institutionDepartment of Human and Environmental Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionPharmacology and Clinical Science Research
dc.contributor.institutionAgriculture, Veterinary and Food Sciences
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.1016/j.ejphar.2014.08.004
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record